2.3 Financial Disclosure Requirements (21 CFR Part 54)

2.3 Financial Disclosure Requirements (21 CFR Part 54)

Objective Data and the Regulatory Purpose of Part 54

The Food and Drug Administration (FDA) implemented 21 CFR Part 54 in 1999 to establish mechanisms for identifying and managing financial conflicts of interest in clinical research. The primary objective of Part 54 is to ensure that financial interests or arrangements do not introduce bias into the design, conduct, or reporting of clinical trials. The FDA relies on clinical trial data to approve new drugs, biological products, and medical devices. If an investigator has a significant financial stake in the success of a product, there is an inherent risk that their evaluation of subjects, reporting of adverse events, or overall clinical judgment could be compromised.

By requiring sponsors to disclose or certify the financial interests of clinical investigators, the FDA can evaluate the integrity of the data submitted in marketing applications. If financial disclosures indicate potential conflicts, the FDA may take steps to verify the data, such as conducting clinical investigator site audits, requiring additional statistical analyses, or requesting that the sponsor conduct additional confirmatory trials.

Key Definitions

To understand the scope of financial disclosure requirements, it is necessary to define the key entities involved:

• Clinical Investigator: Under 21 CFR 54.2(d), a clinical investigator is defined as any listed or identified investigator or sub-investigator who is directly involved in the treatment or evaluation of research subjects. Crucially, the definition also includes the investigator’s spouse and dependent children.
• Covered Clinical Study: Defined as any study of a drug, biological product, or medical device in human subjects submitted in a marketing application (such as a New Drug Application [NDA], Biologics License Application [BLA], or Premarket Approval [PMA]) that the sponsor relies on to establish that the product is safe and effective, or any study where a single investigator makes a significant contribution to the demonstration of safety and efficacy. Phase 1 safety or pharmacokinetic studies are generally excluded from this definition unless they are relied upon to establish effectiveness.
• Sponsor: The entity that initiates and supports the clinical investigation. Under Part 54, the sponsor bears the sole responsibility for collecting financial disclosure information from investigators and submitting certifications or disclosures to the FDA.

Disclosable Financial Arrangements and Reporting Thresholds

Sponsors must collect financial information from all clinical investigators participating in covered clinical studies. There are five specific categories of financial interests that must be disclosed to the FDA, each with its own regulatory threshold:

1. Proprietary Interest in the Tested Product

This includes any proprietary interest in the investigational product, such as a patent, trademark, copyright, licensing agreement, or royalty arrangement.

• Threshold: No dollar threshold. Any proprietary interest, regardless of its current monetary value, must be disclosed.

2. Significant Equity Interest in a Publicly Traded Sponsor

This refers to any ownership interest, including stock, stock options, or other equity, in a sponsor that is publicly traded on a stock exchange.

• Threshold: Value exceeding $25,000 during the time the investigator is carrying out the clinical study and for one year following the completion of the study.

3. Significant Equity Interest in a Non-Publicly Traded Sponsor

This covers any equity interest in a sponsor that is not publicly traded (such as a start-up biotechnology firm).

• Threshold: No dollar threshold. Any equity interest whatsoever (even a single share or stock option) must be disclosed if held during the study or within one year post-completion.

4. Significant Payments of Other Sorts (SPOOS)

These are payments made by the sponsor to the investigator or the investigator’s institution to support activities of the investigator, exclusive of the direct costs of conducting the clinical trial. SPOOS includes honoraria, consulting fees, research grants to conduct other studies, equipment purchases, or retainers.

• Threshold: Cumulative value exceeding $50,000 during the study period and for one year following the completion of the study.

5. Compensation Affected by the Outcome of the Study

This refers to any financial arrangement between the sponsor and the investigator where the value of the compensation could be influenced by the outcome of the study (e.g., a cash bonus paid only if the drug is approved by the FDA, or stock options that vest only upon successful trial completion).

• Threshold: No dollar threshold. All such arrangements are disclosable.

Timelines and Compliance Flow

Compliance with 21 CFR Part 54 requires strict adherence to timelines. The collection of financial data is not a retrospective exercise; it must be integrated into the start-up and close-out phases of a clinical trial:

1. Before Investigator Participation: The sponsor must obtain completed financial disclosure information from each investigator before allowing them to participate in the study (typically collected via a Financial Disclosure Form during the site initiation phase).
2. During the Study: Clinical investigators are under a continuous obligation to update the sponsor if their financial status or holdings change during the course of the clinical trial.
3. One Year Post-Completion: Investigators must track and report any new or modified financial interests for one year following the completion of the study at all sites.
4. Submission with Marketing Application: The sponsor compiles these disclosures and submits them to the FDA when filing the marketing application.

Sponsor Submission Options (FDA Forms)

When submitting a marketing application, the sponsor must submit one of two forms for each covered clinical study:

• Form FDA 3454 (Certification): The sponsor certifies that they have entered into no financial arrangements with the clinical investigators where the value of compensation could be affected by the outcome of the study; that no investigators hold proprietary or significant equity interests; and that no investigator received significant payments of other sorts (SPOOS) exceeding $50,000.
• Form FDA 3455 (Disclosure): The sponsor uses this form if any investigator has a disclosable financial interest. The sponsor must describe the nature of the financial interest, the dollar amount (if applicable), and detail the specific steps taken to minimize the potential for bias (e.g., double-blinding, data analysis by an independent statistician, or utilization of a Multi-Center Study design to dilute the influence of any single investigator's data).

Summary of Financial Disclosure Thresholds